The Biosimilars Initiative changes coverage for specific biologic drugs. Patients and their prescribers have a period of 6 months to discuss switching from an originator brand to a biosimilar brand. Coverage and Special Authority (SA) approval is provided for both originator and biosimilar brands during the switch. Patients unable to switch or who have an adverse response to the biosimilar(s) can seek exceptional SA coverage for the originator.
PharmaCare's strategy to ensure a successful switch includes:
• Involving various practitioners in patient identification, education and support
• Providing time to identify affected patients and guide them through the switch process
• Ensuring patient supports are in place for continuous care
• Having options for those unable to switch or experience challenges with switching
• Identifying areas of concern and providing information for both patients and practitioners
• Providing call-in information sessions and responsive contacts for healthcare practitioners
• Monitoring drug utilization, patient outcomes, and stakeholder feedback
The role of the prescriber in the switch process is paramount. A prescriber sets the tone of the switch discussion, serving as the primary and most trusted information source, facilitates continuity of care, and empowers the patient to expect and realize the best outcomes.
In accordance with Health Canada recommendations, the decision to switch to a biosimilar should be made by a well-informed patient and their prescriber. PharmaCare has created this guide to provide information to support your discussions with affected patients. 
In This Guide
What is changing?
PharmaCare is changing coverage of certain biological drugs, including infliximab.
Coverage for the original biologic (originator) drugs will be discontinued for affected patients, and coverage will instead be provided for their biosimilars: For affected patients with existing Special Authority (SA) approval for infliximab to maintain their coverage, prescribers must write a new prescription, indicating the switch to a biosimilar option. The patient's existing SA remains in effect until the next renewal date (if applicable).
New SA requests and renewals for infliximab will be granted for biosimilar brands.
At this time, coverage of insulin glargine is also changing to biosimilar Basaglar™, and coverage of Lantus® will be discontinued. If your patients may be affected by this change in addition to their infliximab or etanercept, please encourage them to speak with their endocrinologist, general practitioner, nurse practitioner, or Diabetes Education Centre.
Also during Phase 1, patients using Enbrel for rheumatological indications will switch to a biosimilar. Patients using Enbrel for plaque psoriasis will not be affected at this time, as the originator's patent protections currently prevent biosimilars from being approved for that indication.
In Phase 2 of the Biosimilars Initiative, PharmaCare will change coverage for patients taking Remicade for Crohn's disease or ulcerative colitis. The switching of Remicade patients has been designed in two phases to allow for stakeholder engagement and ensure that switch support resources have capacity to address patient and prescriber needs. When do these changes take effect?
Who will be affected?
Plaque psoriasis patients using Remicade who wish to maintain PharmaCare coverage must switch to either Inflectra or Renflexis before November 26, 2019.
All originator and biosimilar brands will be covered during the transition period, May 27, 2019 to November 25, 2019, to provide time for patients to discuss the switch with their prescriber and get a new prescription. Remicade will no longer be covered for Phase 1-affected patients as of November 26, 2019.
If you are unable to discuss switching with a specific patient before the end of the transition period, please contact Biosimilars.Initiative@gov.bc.ca.
Phase 2, affecting patients using Remicade for Crohn's disease or ulcerative colitis, will begin later at a determined date.
Your patients will be affected by the biosimilars initiative beginning May 27, 2019, if they:
• have plaque psoriasis, and
• use Remicade, and
• receive PharmaCare coverage (i.e., have existing SA for infliximab)
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How can I identify which of my patients will be affected?
To assist in identifying which of your patients you may need to speak with about biosimilar switching, we can send you a list of PharmaCare-covered patients who have filled a prescription for Remicade, written by you, in the past 6 months.
Please complete and submit the enclosed HLTH 5841 Patient List Request form. Within two weeks, we will send you a list of names of patients who may be affected.
Will patients need new Special Authority approval?
Patients with existing SA for or infliximab do not require a new SA for the biosimilar. The existing SA remains in effect until the next scheduled renewal date (if applicable). If a patient's SA expires during the transition period, it will be renewed for biosimilar brands only.
Patients with a clinical requirement that prevents switching can have their prescriber submit a new SA request for exceptional coverage of the originator biologic. Exceptional requests will be reviewed by Special Authority on a case-by-case basis.
Note that patients are expected to trial a biosimilar. If a trial has been attempted and halted, the rationale for halting the trial must be well documented in the request for exceptional coverage, and be unlikely to recur or intensify if the patient resumes taking the originator.
What do I need to do to switch patients?
To switch your patients to a biosimilar:
1. Identify an affected patient.
2. Discuss switching to a biosimilar with the patient.
3. Initiate enrollment in the patient support program for the biosimilar and write your patient a new prescription, clearly indicating the biosimilar brand chosen.
Submit the Biosimilar Patient Support Fee with your MSP billing.
5. For any patients unable to switch, submit a new SA request for exceptional coverage of Remicade.
What is the Biosimilar Patient Support Fee?
Why is coverage changing?
The Biosimilar Patient Support Fee is a $50 fee billable to MSP. It is offered in recognition of the additional effort involved in contacting patients and supporting their switch to a biosimilar.
This fee can be claimed once per affected patient during the transition period, regardless of whether that patient switches to a biosimilar. To enable expansion of the PharmaCare formulary and B.C. health services, PharmaCare develops evidence-informed strategies to better optimize how our public resources are used. Biologic drugs represent a huge portion of the annual PharmaCare budget, and biosimilars represent a correspondingly large, but unrealized, opportunity to find value that can be applied to new treatments and services.
In B.C., the biologic drugs being switched (Lantus, Enbrel, and Remicade) represent some of the largest provincial drug expenditures. In 2018, PharmaCare spent $125 million on just these three originator drugs.
Despite being listed preferentially for new starts, the biosimilars for these drugs have captured only a fraction of the market: Basaglar represented only 1.7% of 2018 insulin glargine PharmaCare expenditures, Brenzys and Erelzi only 6.8%, and Inflectra and Renflexis only 5.9%.
PharmaCare is always reviewing new drugs, new indications, and existing coverage and criteria; the provincial formulary must evolve and adapt to the current market, clinical requirements, best practices, and the needs of B.C. residents and practitioners.
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What about patients who cannot switch to a biosimilar?
For patients with a clinical requirement that prevents switching, you can request exceptional coverage of Remicade by submitting a new SA request (HLTH 5380) and clearly identifying why the patient is unable to switch.
Exceptional requests will be reviewed by Special Authority on a case-by-case basis. After an initial review by SA pharmacists, any requests requiring additional input will be submitted to the Drug Benefit and Adjudication Advisory Committee for review by a panel of three dermatologists.
Exceptional requests should be submitted as soon as possible to allow for review, follow-up inquiries, and to ensure uninterrupted coverage.
In Phase 1 of the Biosimilars Initative, the focus is on switching all Lantus users, patients using Remicade for rheumatological or dermatological indications, and those using Enbrel for rheumatological indications.
Phase 2 of the Biosimilars Initiative will focus on switching patients using Remicade for GI indications.
It is likely that further switches to biosimilars will occur for other indications and drugs. All switches will be planned in consultation with the affected prescribers and stakeholders.
Will this be the only biosimilar switch?
PharmaCare is committed to supporting and working with healthcare practitioners throughout the Biosimilars Initiative.
Additional information is available at www.gov.bc.ca/biosimilars/prescribers.
Call-in information sessions, hosted by members of the PharmaCare team and specialist guests, will be scheduled throughout the transition period. An up-to-date schedule of information sessions will be available at the link above.
The PharmaCare team is also available at Biosimilars.Initiative@gov.bc.ca for your questions and feedback.
What if I have questions or need more information?
Are Special Authority criteria for infliximab changing?
There are no changes to the criteria for coverage of infliximab for plaque psoriasis at this time.
Will patient access to infusion centres change?
Biosimilar manufacturers are committed to minimizing the impact of this switch for both patients and prescribers, especially regarding patient support program processes and services, as well as access to infusion clinics. For more information, support, and enrollment forms and assistance, contact the patient support programs below.
INFLECTRA
The Inflectra Patient Assistance Program provides support services, including coordination with private payers and infusion centres, for patients taking Inflectra. After you submit the enrollment form on behalf of your patient, they will be contacted by an Inflectra Navigator. 
How can I support patients with questions and concerns?
Patient acceptance of biosimilars is, understandably, easier to achieve amoung treatment-naïve patients started on a biosimilar. Treatment-experienced, stable patients using an originator biologic may require more support.
The best response to any concern your patient may have is your expertise and experience as a healthcare practitioner, as well as the provision of additional information. Patients who feel they understand the change and why it's necessary, who trust their practitioners, and who understand that there is a support plan in place are more positive and achieve better outcomes.
PharmaCare has created a brief patient information sheet for you to provide to patients to summarize the change and direct them to more detailed resources available at www.gov.bc.ca/biosimilars. Included later in this guide is a biosimilars primer that may be useful in explaining biosimilars to your patients.
The most critical information usually required by patients is that biosimilars:
• are safe and effective
• will work like their current medication
• have no additional risk of adverse reactions or immunological response
• do not require significant changes to their routines or dosing
• are accompanied by patient support programs that will help them with benefits coordination, scheduling, access, etc.
• are available at infusion centres near them (though it may be a different infusion centre than they currently attend)
• are well-understood, that switching from an originator has been extensively studied, and that switch programs have been successful around the world
As an additional resource, Arthritis Consumer Experts have created a Patient Conversation Guide for prescribers to assist in preparing for switch discussions. This guide and many other resources for you and your patients are available at www.gov.bc.ca/biosimilars/prescribers.
It is important to recognize this is a switch process (not a substitution policy), where patient and practitioner education, collaborative decision making, and exception options for those who need them are key.
Healthcare practitioners are essential in empowering patients with information, demonstrating that there is a support system in place, and setting people up for success.
The greatest hurdle for successful switch to a biosimilar is the potential for the nocebo effect, where a patient's negative expectations both psychologically and physiologically affect the outcomes of and adherence to their treatment.
Patients' pre-existing beliefs, previous healthcare experiences, and mindset can have a very real effect on symptoms and their sense of wellbeing.
Many factors contribute to a patient's likelihood of experiencing the nocebo effect:
• Patient factors, such as other mental health comorbidities (especially anxiety, depression, or cognitive impairment), language barriers, a history of negative interactions with the healthcare system, or the use of online media as a source of medical information (where negative responses are highly over-represented, and bias or misrepresentation go unchecked).
• Practitioner factors, such as language choices, manner, non-verbal communication, or unbalanced focus on potential adverse reactions.
• Health care setting factors, such as the physical environment, comfort, ease of access, and interactions with other staff and patients.
• Drug factors, such as an appearance or smell, administration route or routine, change in delivery device, labelling, and price.
A variety of strategies can be effective in preventing the nocebo effect:
• Empower people with information and an active role in the switch process.
• Be attentive and empathetic, so patients feel safe asking questions or expressing concerns.
• Balance the presentation of desired effects and adverse effects.
• Promote a neutral or positive outlook instead of reiterating fears.
• Acknowledge the nocebo effect itself.
• Speak face-to-face, when possible.
• Discuss a plan for follow-up, acknowledging that there are options, no matter the outcome.
What is the nocebo effect and how can I help prevent it?
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What evidence supports biosimilar adoption and switch?
The safety, efficacy, immunogenicity, and therapeutic similarity of biosimilars is evidenced by more than 90 studies involving over 14,000 patients, extensive post-market pharmacovigilance, as well as the results of switch programs in other jurisdictions.
Additional reading and study summaries are available online at www.gov.bc.ca/biosimilars/prescribers.
The Ministry will be carefully monitoring drug utilization, patient outcomes, and the response from patients and healthcare practitioners during and after biosimilar switching in B.C.
Where can I find more resources for my patients?
A library of patient resources is available online at www.gov.bc.ca/biosimilars. Here they can find detailed information about biosimilar switching, how it affects them, biologic and biosimilar drugs, answers to frequently asked questions, and other resources and reading.
If you require additional printed patient information sheets, please contact us at Biosimilars.Initiative@gov.bc.ca.
BIOSIMILAR BASICS A PRIMER FOR PATIENT DISCUSSIONS
What is a biologic drug?
